Stocks · News reference
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates AbCellera Biologics (NASDAQ:ABCL) with a Neutral and announces $13 price target.
AbCellera To Present Phase 2 Data On ABCL635 At IMS 20th World Congress On Menopause
AbCellera (NASDAQ:ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026
What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
Global Drug Discovery AI Tools Market - Strategic Forecast 2026-2032 | Generative AI, Cloud Platforms, and Integrated R&D Workflows Create New Growth Opportunities
A comprehensive market research report examines the growing role of AI tools in drug discovery, covering applications in target identification, molecular design, and preclinical testing. The market is shifting from isolated computational experiments toward integrated workflows combining data systems and laboratory validation. Success depends on data quality, model interpretability, regulatory compliance, and multidisciplinary expertise across biology, chemistry, and data science.
Needham Reiterates Buy on Absci, Maintains $11 Price Target
Needham analyst Gil Blum reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $11 price target.